Sanofi India (BOM:500674) Valuation Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:500674 Sanofi India Ltd BOM:500674
77 GF Score
Price ₹3,369.25
GF Value ₹4,404.20
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Sanofi India Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Sanofi India Valuation Rank Related Terms

BOM:500674
77GF Score
Sanofi India Ltd BOM:500674
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Sanofi India (BOM:500674) Overvalued in 2026?

Based on GuruFocus' analysis, Sanofi India stock appears to be undervalued. The current stock price of ₹3,369.25 is trading 23.5% below its estimated GF Value™ of ₹4,404.20. GuruFocus considers Sanofi India to be Modestly Undervalued.

Key valuation signals for BOM:500674:

  • Valuation Rank:
  • GF Value™: ₹4,404.20 vs. price of ₹3,369.25 (23.5% below fair value)
  • GF Score™: 77/100 with 3 warning signs

No single metric tells the full story. See the BOM:500674 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sanofi India Business Description

Other Exchanges SANOFI:India
Address Saki Vihar Road, Sanofi House, CTS Number 117-B, L&T Business Park, Powai, Mumbai, MH, IND, 400072
Sanofi India Ltd is engaged in the business of manufacturing and trading of drugs and pharmaceuticals. It focuses on a range of therapeutic areas, including diabetes, cardiology, consumer healthcare, hospital, central nervous system, and anti-histamines, among others, and sells its products through independent distributors predominantly in India. The company's products are manufactured in different types of dosage forms, including tablets, capsules (hard and soft), Eye/Ear drops, ampoules, vials, creams, and ointments, and are marketed under different brand names such as Soframycin, Lantus, Cardace, Soliqua, Solian, Thyrogen, Telcite, Zolineg, etc. Geographically, the company generates a majority of its revenue from India, followed by Singapore, and Other markets.
77GF Score

Get the complete analysis for BOM:500674

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹3,369.25
Price
₹4,404.20
GF Value